Introduction
============

Obesity is a worldwide epidemic associated with increased morbidity of chronic diseases, including diabetes, cardiovascular diseases, metabolic syndrome, and cancer. In 2015, 603.7 million adults and 107.7 million children were obese; furthermore, in many countries the incidence of obesity continues to rise, doubling since 1980 ([@B1]). This in turn imposes an enormous burden on the public health system. Many studies have shown that 40--70% of inter-individual variability in obesity can be attributed to genetic factors ([@B52]; [@B23]). Currently, large-scale genome-wide association studies (GWASs) and meta-analyses have successfully identified in excess of 75 loci associated with obesity ([@B10]). Nevertheless, these genetic variability can explain only a minor fraction of obesity cases ([@B19]; [@B33]). This is partly due to the existence of other mechanisms such as epigenetics, gene-environment, and gene-gene interactions, that influence the heritability of obesity ([@B12]; [@B47]). Almost one-third of the genetic variance in the etiology of obesity were due to non-additive factors, according to the family, twin and adoption studies ([@B35]; [@B30]; [@B32]; [@B34]).

SNP-SNP interactions are considered to be potential sources of the unexplained heritability of common diseases ([@B25]). In research to date on the influence of interactions, most studies invariably selected loci based on biological knowledge and known associated loci, studies of genome-wide gene x gene interactions are rare. [@B33] tested SNP-SNP interaction effects among 32 BMI-associated SNPs in their GWAS result, however, no significant results were obtained after multiple test corrections. [@B51] found the interaction rs11847697(PRKD1)-rs9939609 (FTO) associated with BMI via pairwise SNP × SNP interactions analysis based on 34 established BMI-related SNPs in European American adolescents. [@B5] also examined Gene-Gene interactions for abdominal obesity in Chinese population. Nevertheless, these studies ignored genomic regions that were not individually associated but could contribute to disease development if combined.

Until now, following the traditional GWAS approach, genome-wide interaction analyses (GWIAs) were used to investigate SNP-SNP interactions. This method did not need the selection of candidate sites, but computational time was a very large barrier. With the advancement of computing technology, the major barrier has been overcome, and SNP-SNP interaction studies gradually focused on the whole genome level. [@B48] performed GWIAs for BMI using multiple human populations, and found eight interactions that had a significant *P*-value in one or more cohorts. Their studies further demonstrated the GWIA is an effective approach to explain the genetic factor of BMI. SNP-SNP interactions have always been explained by mapping to gene-gene interactions, and genome-wide pathway-based association analysis will further support the interpretation of gene-gene interactions. "Pathway" means a gene set collected from the same biological or functional pathway. Pathway-based association analysis will measure the correlations between phenotypes and gene sets based on the whole genome. This approach can provide additional biological insights and allow one to explore new candidate genes ([@B45]).

Compared to association analysis, fewer studies have assessed potential gene-gene interactions in obesity, and the relatively high heritability of obesity still has not been completely explained. We explored genome-wide IBD (identical by descent) sharing in obese families using linkage with data derived from genome-wide genotyping data, observing an interaction between 2p25-p24 and 13q13-21 that may influence extreme obesity ([@B6]). In the present study, we sought to discover novel susceptibility loci through assessing interaction effects with BMI across the whole genome, and to determine how multiple genetic variants contribute to the development of obesity.

Materials and Methods {#s1}
=====================

Subjects
--------

One thousand and seventy-one (1071) unrelated European American adults were recruited, 1030 of which were females. In this study, we carried out our analyses only in females, comprising 493 extremely obese cases (BMI \> 35 kg/m^2^) and 537 never over-weight controls (BMI \< 25 kg/m^2^). The collection processes have been described in our previous report ([@B46]). All participants gave informed consent, and the investigation protocol was approved by the Committee on Studies Involving Human Beings at the University of Pennsylvania.

Genome-Wide Interaction Analysis
--------------------------------

About 550,000 SNP markers were genotyped by Illumina HumanHap 550 SNP Arrays in our previous GWAS ([@B46]). PLINK 1.90 was used to perform GWIA for BMI. Due to the computational-demand, we used the "--fast-epistasis" command to screen for association. This test was based on a Z-score for the difference in SNP1-SNP2 association (odds ratio) between cases and controls by logistic regression, Z = \[log(R)-log(S)\]/sqrt\[SE(R) + SE(S)\], where R and S are the odds ratios in cases and controls, respectively ([@B31]). We excluded SNPs of minor allele frequencies (MAF) \< 5%. After frequency and genotyping pruning, 497174 SNPs were used to carry out interaction analyses. A total of 123,590,744,551 valid SNP-SNP tests were performed. We then selected the SNPs with interaction *P* \< 1 × 10^-8^ (Bonferroni-corrected significant threshold *P* = 4.05 × 10^-13^) to analyze interactions by logistic regression based on allele dosage for each SNP.

Haplotype-Based Association Analysis
------------------------------------

Eight hundred and thirty-one (831) SNP-SNP interactions showed *P* \< 10^-8^ in the results of the SNP-SNP interaction tests based on Z-scores. In order to rule out the possibility of an accidental finding, we mapped these SNPs to genes, then excluded the SNP-SNP interactions by the following criteria: ① neither SNPs exist in genes; ② either of the two SNPs exist independently in a gene. Through the above exclusion criteria, the rs7800006(*EXOC4*)-rs10797020(1q23.1) interaction was the most significant (*P* = 2.63 × 10^-11^), where there were 39 interactions with *P* \< 10^-8^ between *EXOC4* and 1q23.1. Five SNPs exist in the *EXOC4* gene region and 9 SNPs exist in the 1q23.1 region, but their interaction *P*-value did not pass Bonferroni multiple tests. However, the Bonferroni correction test is highly conservative and would overcorrect for the non-independent SNPs, which fall within blocks of strong linkage disequilibrium (LD) ([@B8]). [@B26] have reported that haplotype-based association analyses are more powerful than single allele-based methods when multiple disease-susceptibility mutations occur within the same gene. [@B9] also have pointed out that haplotypes are useful during disease development due to the interaction of multiple cis-acting susceptibility variants located at the gene.

Therefore, in case of producing false negatives, we selected the 5 SNPs that exist in *EXOC4* and the 9 SNPs that exist in 1q23.1, respectively, for the next haplotype-based association analysis, which were conducted by PLINK1.07. The haplotype windows were defined at two SNPs, three SNPs, and four SNPs.

Genome-Wide Pathway-Based Association Analysis
----------------------------------------------

To further study the gene-gene interactions by pathway analysis, the GenGen program was used to analyze pathway-based association based on the modified Gene Set Enrichment Algorithm (GSEA) ([@B36]; [@B44]). The calculation steps have been outlined previously ([@B20]). In this study, a total of 518230 SNPs passed the quality-control thresholds of minor allele frequencies \> 0.01 and Hardy-Weinberg equilibrium \> 0.001, which covered 17,438 genes, mapping SNPs to 20 kb upstream and downstream of each gene. A total of 1347 gene sets were selected from BioCarta, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Ontology (GO) databases, gene set sizes were between 5 and 200 genes.

Replication of the Pathway-Based Association Results
----------------------------------------------------

We further attempted to replicate the GenGen results in data sets from the GIANT (*N* = 339,224) ([@B23]), ENGAGE (*N* = 87,048) ([@B13]), and DIAGRAM (*N* = 119,688) ([@B49]) consortia. Given that no phenotypes and genotypes were available online from the three consortia, GSA-SNP software ([@B27]) was carried out to perform the pathway associations analyses using the GWAS *P*-values. To better compare with GenGen analysis results, we obtained SNP specific *P*-values from GIANT, ENGAGE, and DIAGRAM GWASs, and the same SNPs identified by the GenGen analysis were selected for the pathway association analysis for BMI in the three consortium data sets.

As described above, the flow chart of experimental analysis was shown in [Figure 1](#F1){ref-type="fig"}.

![The flow chart of experimental analysis.](fgene-10-00404-g001){#F1}

Results
=======

The average age of the 1030 female subjects was 42.2 ± 9.0 years (range, 17--65 years). In our study, we defined BMI \> 35 kg/m^2^ as "cases," *N* = 493, and BMI \< 25 kg/m^2^ as "controls," *N* = 537 ([Figure 2](#F2){ref-type="fig"}). Distributions of BMI in cases and controls are shown in [Table 1](#T1){ref-type="table"}.

![Violin plots of BMI in 1030 samples. Cases (BMI \> 35 kg/m^2^, *N* = 493), and controls (BMI \< 25 kg/m^2^, *N* = 537).](fgene-10-00404-g002){#F2}

###### 

BMI distributions in cases and controls.

             N     Age          BMI (kg/m^2^)   Maximum   Minimum   Mean   Std. Deviation
  ---------- ----- ------------ --------------- --------- --------- ------ ----------------
  Cases      493   41.0 ± 9.2   \>35.0          97.0      35.6      49.4   8.7
  Controls   537   43.3 ± 8.6   \<25.0          25.0      16.0      20.1   1.8

Genome-Wide Interaction Analysis
--------------------------------

GWIA based on Z-score of BMI determined 831 SNP-SNP interactions with *P* \< 10^-8^, those with *P* \< 1 × 10^-9^ were shown in [Figure 3](#F3){ref-type="fig"}. To avoid errors caused by chance and rare genotypes, some interactions were excluded according to the exclusion criteria, which has been described in method. rs7800006*(EXOC4*)-rs10797020(1q23.1) interaction yielded the lowest *P*-value (*P* = 2.63 × 10^-11^) after screening by exclusion criteria, but did not pass the threshold for multiple testing (*P* \< 4.05 × 10^-13^). Fourteen SNPs resulted in 39 interactions that had *P* \< 10^-8^ between *EXOC4* and 1q23.1. Five SNPs (rs10954428, rs12540206, rs6963221, rs7800006, and rs6976491) were found in the *EXOC4* gene region, while 9 SNPs (rs1578761, rs975118, rs10489833, rs10797020, rs11264997, rs7512592, rs6679056, rs1873511, and rs6697656) were found in 1q23.1among which the maximum distance is 70.4 kb ([Table 2](#T2){ref-type="table"}).

![Circos visualization of mapped SNP-SNP interactions for BMI (*P* \< 1 × 10^-9^). The curves represent the interactions between the two SNPs, and the color gradually changes from red to blue as the *P*-value decreases.](fgene-10-00404-g003){#F3}

###### 

Genotype interactions (epistasis) associated with BMI.

  SNP1         MAF1    Gene1     SNP2         MAF2    Gene2                       *P*-value^∗^ (allele dosage)   *P*-value^∗∗^ (Z-score)
  ------------ ------- --------- ------------ ------- --------------------------- ------------------------------ -------------------------
  rs10954428   0.339   *EXOC4*   rs10797020   0.449   Between OR10R1P and OR6Y1   4.24 × 10^-8^                  1.44 × 10^-8^
  rs10954428   0.339   *EXOC4*   rs1578761    0.452   Between OR10R1P and OR6Y1   2.04 × 10^-7^                  8.66 × 10^-8^
  rs10954428   0.339   *EXOC4*   rs10489833   0.450   Between OR10R1P and OR6Y1   6.25 × 10^-8^                  2.26 × 10^-8^
  rs10954428   0.339   *EXOC4*   rs11264997   0.452   Between OR10R1P and OR6Y1   8.54 × 10^-8^                  3.21 × 10^-8^
  rs12540206   0.424   *EXOC4*   rs1578761    0.452   Between OR10R1P and OR6Y1   4.95 × 10^-9^                  1.21 × 10^-9^
  rs12540206   0.424   *EXOC4*   rs975118     0.453   Between OR10R1P and OR6Y1   3.43 × 10^-9^                  7.92 × 10^-10^
  rs12540206   0.424   *EXOC4*   rs10489833   0.450   Between OR10R1P and OR6Y1   1.97 × 10^-9^                  4.19 × 10^-10^
  rs12540206   0.424   *EXOC4*   rs10797020   0.449   Between OR10R1P and OR6Y1   7.25 × 10^-10^                 1.26 × 10^-10^
  rs12540206   0.424   *EXOC4*   rs11264997   0.452   Between OR10R1P and OR6Y1   1.70 × 10^-9^                  3.41 × 10^-10^
  rs12540206   0.424   *EXOC4*   rs7512592    0.450   Between OR10R1P and OR6Y1   1.97 × 10^-9^                  4.19 × 10^-10^
  rs12540206   0.424   *EXOC4*   rs1873511    0.453   OR10R3P                     4.38 × 10^-9^                  1.04 × 10^-9^
  rs12540206   0.424   *EXOC4*   rs6697656    0.452   Between OR6Y1 and OR6P1     1.13 × 10^-8^                  3.28 × 10^-9^
  rs6963221    0.413   *EXOC4*   rs1578761    0.452   Between OR10R1P and OR6Y1   9.53 × 10^-9^                  2.67 × 10^-9^
  rs6963221    0.413   *EXOC4*   rs975118     0.453   Between OR10R1P and OR6Y1   6.81 × 10^-9^                  1.83 × 10^-9^
  rs6963221    0.413   *EXOC4*   rs10489833   0.450   Between OR10R1P and OR6Y1   3.81 × 10^-9^                  9.33 × 10^-10^
  rs6963221    0.413   *EXOC4*   rs10797020   0.449   Between OR10R1P and OR6Y1   1.43 × 10^-9^                  2.87 × 10^-10^
  rs6963221    0.413   *EXOC4*   rs11264997   0.452   Between OR10R1P and OR6Y1   2.40 × 10^-9^                  5.29 × 10^-10^
  rs6963221    0.413   *EXOC4*   rs7512592    0.450   Between OR10R1P and OR6Y1   3.81 × 10^-9^                  9.33 × 10^-10^
  rs6963221    0.413   *EXOC4*   rs6679056    0.471   OR10R2                      2.58 × 10^-8^                  8.63 × 10^-9^
  rs6963221    0.413   *EXOC4*   rs1873511    0.453   OR10R3P                     6.21 × 10^-9^                  1.61 × 10^-9^
  rs6963221    0.413   *EXOC4*   rs6697656    0.452   Between OR6Y1 and OR6P1     2.11 × 10^-8^                  6.83 × 10^-9^
  rs6976491    0.423   *EXOC4*   rs1578761    0.452   Between OR10R1P and OR6Y1   7.46 × 10^-9^                  2.01 × 10^-9^
  rs6976491    0.423   *EXOC4*   rs975118     0.453   Between OR10R1P and OR6Y1   5.11 × 10^-9^                  1.31 × 10^-9^
  rs6976491    0.423   *EXOC4*   rs10489833   0.450   Between OR10R1P and OR6Y1   3.00 × 10^-9^                  7.00 × 10^-10^
  rs6976491    0.423   *EXOC4*   rs10797020   0.449   Between OR10R1P and OR6Y1   1.13 × 10^-9^                  2.16 × 10^-10^
  rs6976491    0.423   *EXOC4*   rs11264997   0.452   Between OR10R1P and OR6Y1   1.89 × 10^-9^                  4.01 × 10^-10^
  rs6976491    0.423   *EXOC4*   rs7512592    0.450   Between OR10R1P OR6Y1       3.00 × 10^-9^                  7.00 × 10^-10^
  rs6976491    0.423   *EXOC4*   rs6679056    0.471   OR10R2                      2.09 × 10^-8^                  7.03 × 10^-9^
  rs6976491    0.423   *EXOC4*   rs1873511    0.453   OR10R3P                     4.81 × 10^-9^                  1.20 × 10^-9^
  rs6976491    0.423   *EXOC4*   rs6697656    0.452   Between OR6Y1 and OR6P1     1.68 × 10^-8^                  5.30 × 10^-9^
  rs7800006    0.427   *EXOC4*   rs1578761    0.452   Between OR10R1P and OR6Y1   1.31 × 10^-9^                  2.65 × 10^-10^
  rs7800006    0.427   *EXOC4*   rs975118     0.453   Between OR10R1P and OR6Y1   8.72 × 10^-10^                 1.66 × 10^-10^
  rs7800006    0.427   *EXOC4*   rs10489833   0.447   Between OR10R1P and OR6Y1   5.26 × 10^-10^                 9.00 × 10^-11^
  rs7800006    0.427   *EXOC4*   rs10797020   0.449   Between OR10R1P and OR6Y1   1.96 × 10^-10^                 2.63 × 10^-11^
  rs7800006    0.427   *EXOC4*   rs11264997   0.452   Between OR10R1P and OR6Y1   4.42 × 10^-10^                 7.09 × 10^-11^
  rs7800006    0.427   *EXOC4*   rs7512592    0.450   Between OR10R1P and OR6Y1   5.26 × 10^-10^                 9.00 × 10^-11^
  rs7800006    0.427   *EXOC4*   rs6679056    0.471   OR10R2                      6.87 × 10^-9^                  1.98 × 10^-9^
  rs7800006    0.427   *EXOC4*   rs1873511    0.453   OR10R3P                     1.12 × 10^-9^                  2.19 × 10^-10^
  rs7800006    0.427   *EXOC4*   rs6697656    0.452   Between OR6Y1 and OR6P1     3.10 × 10^-9^                  7.41 × 10^-10^

∗

Interaction analysis based on allele dosage for each SNP.

∗∗

Interaction analysis based on Z-score.

MAF, minor allele frequency.

Haplotype-Based Association Analysis
------------------------------------

Due to the highly conservative of Bonferroni correction test, false negatives were prone. We selected the above-mentioned 14 SNPs located in *EXOC4* or 1q23.1 for haplotype-based association analyses. The SNPs showed LD in both *EXOC4* (D' \> 0.94), and 1q23.1 (D' \> 0.99) (Supplement Figure [1](#SM2){ref-type="supplementary-material"}). Two-locus haplotype analysis revealed that rs6963221\| rs7800006 (A\| C) was associated with BMI (*P* = 0.013). BMI was also influenced by three-locus haplotypes rs6963221\| rs7800006\| rs12540206 (A\|C\|date, fewer studies have examined T, *P* = 0.025), rs6963221\| rs7800006\| rs10954428 (A\|C\|G, *P* = 0.018) and the four-locus haplotype rs6963221\| rs7800006\| rs12540206\| rs10954428 (A\|C\|T\|G, *P* = 0.033) ([Table 3](#T3){ref-type="table"}). The four SNPs are in *EXOC4*, indicating that *EXOC4* associated with BMI.

###### 

Haplotype analysis of *EXOC4* gene SNPs.

  SNPs                                              Haplotype   F_A^∗^   F_U^∗∗^   χ^2^    DF   *P*
  ------------------------------------------------- ----------- -------- --------- ------- ---- -------
  rs6963221\| rs7800006                             AC          0.036    0.015     6.146   1    0.013
  rs6963221\| rs7800006\| rs12540206                ACT         0.032    0.014     5.026   1    0.025
  rs6963221\| rs7800006\| rs10954428                ACG         0.033    0.014     5.624   1    0.018
  rs6963221\| rs7800006\| rs12540206\| rs10954428   ACTG        0.029    0.013     4.559   1    0.033

∗

Frequency in cases.

∗∗

Frequency in controls.

Genome-Wide Pathway-Based Association Analysis
----------------------------------------------

In the genome-wide pathway-based association study carried out with GenGen, 43 pathways achieved a significance of empirical *P* \< 0.05 ([Figure 4](#F4){ref-type="fig"} and Supplement Table [1](#SM1){ref-type="supplementary-material"}). The Tob1 pathway (role of Tob in T-cell activation) showed the most significant association with BMI (empirical *P* \< 0.001, FDR = 0.044, FWER = 0.040, [Table 4](#T4){ref-type="table"}). Empirical *P*-values (denoted as "nominal *P*" values by the GenGen program) were calculated based on the 1000 phenotype permutations.

![Distribution of empirical *P*-FDR for BMI. Empirical *P*-FDR for BMI- related pathways (empirical *P* \< 0.05, denoted as "nominal" *P*-values in the GenGen program) obtained by modified GSEA (GenGen), *Tob1* pathway is indicated by the arrow.](fgene-10-00404-g004){#F4}

###### 

Pathway-based association study for BMI.

  Pathway ID    Gene set                           Consortium   Empirical *P*   *P*     Corrected-*P*^∗^   FDR^∗∗^   FWER^∗∗∗^   Method
  ------------- ---------------------------------- ------------ --------------- ------- ------------------ --------- ----------- ---------
  tob1Pathway   Role of Tob in T-cell activation   Our-data     \<0.001                                    0.044     0.040       GenGen
  GO0051169     Nuclear                            GIANT                        0.048   0.622              0.015                 GSA-SNP
                transport                          ENGAGE                       0.041   0.329              0.036                 GSA-SNP
  hsa04530      Tight                              ENGAGE                       0.004   0.487              0.032                 GSA-SNP
                junction                           DIAGRAM                      0.001   0.277              0                     GSA-SNP
  GO0030165     PDZ                                GIANT                        0.032                      0                     GSA-SNP
                domain binding                     ENGAGE                       0.028                      0.034                 GSA-SNP

∗

Benjamini and Hochbaum false discovery rate (

Benjamini and Hochberg, 1995

).

∗∗

False discovery rate used by

Subramanian et al. (2005)

.

∗∗∗

Family wise-error rate.

Replication studies were conducted in data sets from the GIANT, ENGAGE, and DIAGRAM consortia by GSA-SNP. The Tob1 pathway did not have a significant *P*-value in these settings. However, the pathway GO0051169 (nuclear transport) containing TOB1 was associated with BMI in GIANT and ENGAGE consortia, and passed FDR correction for multiple testing (*P*~GIANT~ = 0.048, FDR~GIANT~ = 0.015; *P*~ENGAGE~ = 0.041, FDR~ENGAGE~ = 0.036, [Table 4](#T4){ref-type="table"}). The EXOC4-contained pathway hsa04530 was also associated with BMI in ENGAGE and DIAGRAM consortium data sets by GSA-SNP ([Table 4](#T4){ref-type="table"}). GO0030165 containing *EXOC4* was also related to BMI in the GIANT and ENGAGE consortium data sets and passed FDR correction ([Table 4](#T4){ref-type="table"}).

Discussion
==========

In the context of genetic epidemiology, although GWASs have found the majority of BMI-related genes identified to date, combined these loci explain only about 4% of the phenotypic variation of BMI ([@B24]). Modest and rare variants have been ignored by the GWASs, partly because of the other mechanisms, including epigenetics, gene-gene and gene-environment interactions, and statistical issues ([@B12]; [@B47]; [@B3], [@B4]; [@B18]). To date, fewer studies have examined the effects of interactions on obesity. Despite this, some obesity-related interactions still have been found, including *PRKD1*-*FTO* and *WNT4*-*WNT5A* ([@B48]; [@B51]; [@B7]). Pathway-based analysis is an alternative approach to detect gene interactions. [@B22] had found that the vasoactive intestinal peptide pathway was significantly correlated with BMI and fat mass, suggesting that this pathway plays an important role in the development of obesity. Our previous studies also revealed that the Rac1pathway was associated with the obesity-related phenotype plasma adiponectin ([@B20]).

In the present study, our GWIA for BMI found an interaction between *EXOC4* and 1q23.1 that may contribute to the development of obesity, although this interaction did not pass the Bonferroni correction test, they had the lowest interaction *P*-value (*P* = 4.05 × 10^-13^) after accidental exclusion. To further examine whether *EXOC4* and 1q23.1 were related to BMI, we selected the SNPs locate in *EXOC4* and 1q23.1 accordingly base on the results of GWIA to carry out haplotype-based association analyses, the results verified that *EXOC4* contributed to BMI. In genome-wide pathway-based association studies, the relation between the *TOB1* pathway and BMI was identified. *EXOC4* and *TOB1* associated with BMI were replicated in GIANT, ENGAGE, and DIAGRAM data sets. To our knowledge, these findings have not been identified having main effects in previous BMI-related studies.

*EXOC4* (exocyst complex component 4, also known as *SEC8*) is a component of the exocyst complex involved in the targeting of exocytic vesicles, which participate in temporal and spatial regulation of exocytosis ([@B14]; [@B40]). Numerous research results show that exocysts interact directly or indirectly with many proteins including cell membranes, cytoskeletal, the small GTPases and other proteins in the cell cortex ([@B50]; [@B39]). Tanaka et al. indicated that *EXOC4* modulates cell migration by controlling the *ERK* and p38 *MAPK* signaling pathways ([@B39]). They also found that *EXOC4* can mediate cell migration and adhesion via controlling Smad3/4 expression through CBP ([@B38]).

*EXOC4* is located in a widely replicated obesity linkage peak on chromosome 7q22-q36 ([@B11]; [@B21]), and has been connected with various diseases, such as type 2 diabetes, cancer, and neuronal disorders. GLUT4 (glucose transporter 4) transports most of the glucose in muscle and adipose tissue; the docking and tethering of the GLUT4 vesicle to the plasma membrane is mediated via *EXOC4* ([@B15]; [@B16]). A population genetic study also identified several type 2 diabetes-associated SNPs near *EXOC4* in The NHLBI Family Heart Study ([@B17]).

Nineteen genes are involved in BMI-related Tob1 pathway (role of Tob in T-cell activation): *TOB1, TOB2, IFNG, IL2, IL2RA, IL4, SMAD3, SMAD4, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2, TGFBR3, CD3D, CD3E, CD3G, CD247*, and *CD28*. This pathway is a component of balanced functioning of the immune system. TOB1 represses T cell activation and is a member of a family of genes with anti-proliferative properties. Research has shown that TOB1 interacts with the TGF (transforming growth factor) and can stimulate transcription factors *SMAD4* and *SMAD2*, increasing their binding to the *IL-2* promoter and helping to repress *IL-2* expression, suggesting that interference in TOB1 function be associated with autoimmune disease ([@B42]; [@B41]; [@B12]). Numerous studies have found a significant correlation between obesity and many autoimmune diseases, adipokines such as leptin, adiponectin and resistin may be key players in interactions among them ([@B43]).

TOB1and TOB2 belong to the TOB family of anti-proliferative proteins that have the potential to regulate cell growth. As a repressor of the p38/*MAPK* pathway, *TOB1* can suppress p38/*MAPK* signaling by decreasing phosphorylation of p38 and *ATF2* ([@B37]; [@B28]); p38/*MAPK* acts as an enhancer of adipogenesis contributes to obesity ([@B29]). The miR-32-*TOB1*-*FGF21* pathway can regulate brown adipose tissue adipocyte function and development and is associated with obesity and metabolic syndrome ([@B28]). The biological functions mentioned above are consistent with our study results and provided evidence of a direct connection between *TOB1* and obesity.

Traditional GWASs have identified many obesity-associated genes, however, additional loci have yet to be identified. *EXOC4* and *Tob1* pathway genes may be among these from our GWIA and genome-wide pathway-based association analysis.

EXOC4 join in the tight junction signal pathway: this pathway receives not only assembly signals but also transmit information ([@B53]). Therefore, EXOC4 may play a role in signal transmission from sensory perception to the brain, thus affecting obesity. The Tob1 pathway may contribute to obesity through the MAPK pathway. Needless to say, molecular biological experiments are needed to repeat the results. For the GWASs, statistical replication is the golden rule to prevent false positives. Although our findings were replicated in different populations with different methods, it also needs to be confirmed in larger populations by GWIAs.
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